US Stock MarketDetailed Quotes

APLS Apellis Pharmaceuticals

Watchlist
  • 30.770
  • +3.020+10.88%
Close Nov 22 16:00 ET
  • 30.820
  • +0.050+0.16%
Post 20:01 ET
3.83BMarket Cap-15157P/E (TTM)

About Apellis Pharmaceuticals Company

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Company Profile

SymbolAPLS
Company NameApellis Pharmaceuticals
Listing DateNov 9, 2017
Issue Price14.00
Founded2009
CEODr. Cedric Francois, M.D.
MarketNASDAQ
Employees706
Fiscal Year Ends12-31
Address100 5th Avenue
CityWaltham
ProvinceMassachusetts
CountryUnited States of America
Zip Code02451-8703
Phone1-617-977-5700

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Cedric Francois, M.D.
  • Director, Chief Executive Officer and President
  • 10.37M
  • Mark Jeffrey DeLong
  • Chief Business and Strategy Officer
  • --
  • Dr. Caroline Baumal, M.D.
  • Chief Medical Officer
  • 4.43M
  • Timothy E. Sullivan
  • Chief Financial Officer and Treasurer
  • 3.74M
  • Pascal Deschatelets, PhD
  • Chief Scientific Officer
  • --
  • Nur Nicholson
  • Chief Technical Operations Officer
  • --
  • James George Chopas
  • Vice President, Corporate Controller and Chief Accounting Officer
  • --
  • Dr. Jeffrey Eisele, PhD
  • Chief Development Officer
  • --
  • Karen Lewis
  • Chief People Officer
  • --
  • Adam J. Townsend
  • Chief Operating Officer
  • 3.71M
  • Dr. Gerald L. Chan, Sc.D.
  • Chairman of the Board
  • 504.08K
  • A. Sinclair Dunlop
  • Independent Director
  • 480.96K
  • Alec Machiels
  • Independent Director
  • 495.96K
  • Stephanie Monaghan O’Brien
  • Independent Director
  • 488.46K
  • Paul Fonteyne, M.S.
  • Independent Director
  • 489.08K
  • David Watson
  • General Counsel
  • 4.89M

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data